Literature DB >> 23290275

The clinical impact of the American College of Surgeons Oncology Group Z-0011 trial--results from the BreastSurgANZ National Breast Cancer Audit.

Rachel K Ainsworth1, James Kollias, Abbey Le Blanc, Primali De Silva.   

Abstract

INTRODUCTION: The publication of the American College of Surgeons Oncology Group (ACOSOG) Z-0011 Trial concluded that axillary lymph node clearance is no longer necessary for women having breast conserving treatment with 1-2 positive axillary sentinel lymph glands. The current study was designed to investigate the clinical impact of the Z-0011 Trial in breast surgical practice.
MATERIALS AND METHODS: The BreastSurgANZ National Breast Cancer Audit database was interrogated for women treated between 2005 and 2010 who would have met the entry criteria for the Z-0011 Trial. This group was then calculated as a proportion of the total breast cancer episodes treated during this period.
RESULTS: A total of 64,883 cases of breast cancer were eligible for analysis. 22,731 underwent breast conserving surgery and sentinel node biopsy for invasive breast cancer. A total of 4482 cases (6.9%) fulfilled the criteria for Z-11 Trial.
CONCLUSION: Although the ACOSOG Z-0011 Trial has important implications for sentinel node positive cases undergoing breast conserving treatment, the overall impact of the Trial in breast clinical practice is small. It cannot be described as "practice changing". Women who fulfil the entry criteria for the Z-0011 Trial should be informed of the clinical relevance of the trial and be permitted to participate in informed discussions with members of the multidisciplinary team regarding their treatment options.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Keywords:  Axillary lymph node; Early breast cancer; Sentinel node biopsy; Z-0011

Mesh:

Year:  2013        PMID: 23290275     DOI: 10.1016/j.breast.2012.11.005

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  5 in total

1.  Management of the axilla: has Z0011 had an impact?

Authors:  D P Joyce; A J Lowery; L B McGrath-Soo; E Downey; L Kelly; G T O'Donoghue; M Barry; A D K Hill
Journal:  Ir J Med Sci       Date:  2015-01-17       Impact factor: 1.568

2.  The Relevance of Ultrasound Imaging of Suspicious Axillary Lymph Nodes and Fine-needle Aspiration Biopsy in the Post-ACOSOG Z11 Era in Early Breast Cancer.

Authors:  Gopal R Vijayaraghavan; Srinivasan Vedantham; Milliam Kataoka; Carolynn DeBenedectis; Robert M Quinlan
Journal:  Acad Radiol       Date:  2016-12-01       Impact factor: 3.173

3.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases: commentary on the IBCSG 23-01 Trial.

Authors:  Tina J Hieken; Judy C Boughey
Journal:  Gland Surg       Date:  2013-08

4.  Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.

Authors:  Franco Di Filippo; Simona Di Filippo; Anna Maria Ferrari; Raffaele Antonetti; Alessandro Battaglia; Francesca Becherini; Laia Bernet; Renzo Boldorini; Catherine Bouteille; Simonetta Buglioni; Paolo Burelli; Rafael Cano; Vincenzo Canzonieri; Pierluigi Chiodera; Alfredo Cirilli; Luigi Coppola; Stefano Drago; Luca Di Tommaso; Privato Fenaroli; Roberto Franchini; Andrea Gianatti; Diana Giannarelli; Carmela Giardina; Florence Godey; Massimo M Grassi; Giuseppe B Grassi; Siobhan Laws; Samuele Massarut; Giuseppe Naccarato; Maria Iole Natalicchio; Sergio Orefice; Fabrizio Palmieri; Tiziana Perin; Manuela Roncella; Massimo G Roncalli; Antonio Rulli; Angelo Sidoni; Corrado Tinterri; Maria C Truglia; Isabella Sperduti
Journal:  J Exp Clin Cancer Res       Date:  2016-12-08

5.  Impact of surgical intervention trials on healthcare: A systematic review of assessment methods, healthcare outcomes, and determinants.

Authors:  Juliëtte J C M van Munster; Amir H Zamanipoor Najafabadi; Nick P de Boer; Wilco C Peul; Wilbert B van den Hout; Peter Paul G van Benthem
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.